Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niraparib companion diagnostic - Myriad Genetics

Drug Profile

Niraparib companion diagnostic - Myriad Genetics

Alternative Names: BRACAnalysis (Niraparib); Niraparib - BRACAnalysis; Niraparib - BRACAnalysis CDx

Latest Information Update: 02 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myriad Genetics
  • Developer GSK; Myriad Genetics; TESARO
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 02 Jan 2023 Launched for Breast cancer (Diagnosis) in USA (Myriad Genetics pipeline, January 2023)
  • 28 Sep 2020 No development reported - Phase-III for Breast cancer (Diagnosis) in United Kingdom, Spain, Portugal, Poland, Netherlands, Italy, Israel, Israel, Iceland, Hungary, Greece, France, England, Canada, Belgium, USA (unspecified route)
  • 28 Sep 2020 No development reported - Phase-III for Fallopian tube cancer (Diagnosis) in United Kingdom, Sweden, Spain, Poland, Norway, Israel, Italy, Hungary, France, Germany, Denmark, Canada, Belgium, Austria (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top